| DB ID | MyCo_3207 |
| Title | A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit |
| Year | 2017 |
| PMID | 28384600 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | parapsilosis |
| Organism | Candida parapsilosis |
| Ethical Statement | Prior approval for this study was obtained from the St. James’s Hos- pital Research Ethics Committee (Reference 2012/39/01). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Ireland |
| Cohort | A total of 100 patients were recruited in the study. |
| Cohort No. | 100 |
| Age Group | 20–85 |
| P Value | p<0.0001 |
| Sensitivity | 0.63 |
| Specificity | 0.83 |
| Positive Predictive Value | 0.65 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
